Datamonitor expects to see an excessive, but stable, number of prevalent cases of dyslipidemia in all of the seven major markets, with the majority of cases seen in the US and Germany. Between 2011 and 2021, Datamonitor forecasts dyslipidemia prevalent cases in the seven major markets to increase by only 0.7%.
Between 2011 and 2021, Datamonitor forecasts prevalent cases of dyslipidemia in the seven major markets will remain stable, increasing from 123.9 million cases in 2011 to 132.5 million prevalent cases in 2021. Each of the seven major markets will experience marginal increases in prevalent dyslipidemia cases (0.1% to 1.2%) between 2011 and 2021.
Your key questions answered
What are the most robust sources for dyslipidemia prevalence data?
How will the patient population change over the next decade in the seven major markets?
What are the major risk factors for dyslipidemia that are driving the trend in prevalent cases and how are they changing?
Major points covered in Table of Contents of this report include:
- OVERVIEW
- EXECUTIVE SUMMARY
- DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
- GLOBAL VARIATION AND HISTORICAL TRENDS
- DRIVERS OF DYSLIPIDEMIA EPIDEMIOLOGY
- EPIDEMIOLOGIC FORECASTING OF DYSLIPIDEMIA
- EPIDEMIOLOGIC RESULTS
Report Details :
Published: February 2012
No.of Pages:
Price: Single User License – US $ 5700
Corporate User License- US $ 14250
No comments:
Post a Comment